Ubs Group Ag Uni Qure N.V. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Uni Qure N.V. stock. As of the latest transaction made, Ubs Group Ag holds 4,966 shares of QURE stock, worth $28,306. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,966

Previous 5,075 2.15%

Holding current value

$28,306

Previous $22,000 9.09%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.78 - $10.12 $412 - $1,103	-109 Reduced 2.15%	4,966 $24,000
Q2 2024 Aug 13, 2024	SELL	$4.39 - $5.43 $94,968 - $117,467	-21,633 Reduced 81.0%	5,075 $22,000
Q1 2024 May 13, 2024	SELL	$4.82 - $6.93 $681,037 - $979,167	-141,294 Reduced 84.1%	26,708 $138,000
Q4 2023 Feb 09, 2024	BUY	$5.63 - $8.27 $459,030 - $674,277	81,533 Added 94.29%	168,002 $1.14 Million
Q3 2023 Nov 09, 2023	BUY	$6.71 - $11.83 $466,566 - $822,575	69,533 Added 410.56%	86,469 $580,000
Q2 2023 Aug 11, 2023	SELL	$11.12 - $22.2 $751,889 - $1.5 Million	-67,616 Reduced 79.97%	16,936 $194,000
Q1 2023 May 12, 2023	SELL	$18.7 - $23.07 $744,933 - $919,016	-39,836 Reduced 32.03%	84,552 $1.7 Million
Q4 2022 Feb 08, 2023	BUY	$18.12 - $27.32 $1.37 Million - $2.07 Million	75,730 Added 155.64%	124,388 $2.82 Million
Q3 2022 Nov 10, 2022	SELL	$16.98 - $25.54 $385,921 - $580,473	-22,728 Reduced 31.84%	48,658 $912,000
Q2 2022 Aug 10, 2022	SELL	$13.15 - $20.45 $1.83 Million - $2.84 Million	-138,794 Reduced 66.04%	71,386 $1.33 Million
Q1 2022 May 16, 2022	BUY	$14.54 - $21.5 $909,491 - $1.34 Million	62,551 Added 42.37%	210,180 $3.8 Million
Q4 2021 Feb 14, 2022	BUY	$20.24 - $36.01 $2.04 Million - $3.63 Million	100,777 Added 215.1%	147,629 $3.06 Million
Q3 2021 Nov 15, 2021	BUY	$26.01 - $38.22 $322,315 - $473,622	12,392 Added 35.96%	46,852 $1.5 Million
Q2 2021 Aug 13, 2021	SELL	$29.97 - $37.17 $1.18 Million - $1.46 Million	-39,310 Reduced 53.29%	34,460 $1.06 Million
Q1 2021 May 12, 2021	BUY	$29.24 - $42.03 $1.79 Million - $2.58 Million	61,305 Added 491.82%	73,770 $2.49 Million
Q4 2020 Feb 11, 2021	SELL	$35.35 - $50.67 $897,501 - $1.29 Million	-25,389 Reduced 67.07%	12,465 $450,000
Q3 2020 Nov 12, 2020	BUY	$35.98 - $47.66 $476,806 - $631,590	13,252 Added 53.87%	37,854 $1.39 Million
Q2 2020 Jul 31, 2020	SELL	$45.06 - $67.74 $436,406 - $656,061	-9,685 Reduced 28.25%	24,602 $1.11 Million
Q1 2020 May 01, 2020	BUY	$40.01 - $73.97 $389,737 - $720,541	9,741 Added 39.68%	34,287 $1.63 Million
Q4 2019 Feb 14, 2020	BUY	$37.13 - $74.62 $47,266 - $94,991	1,273 Added 5.47%	24,546 $1.76 Million
Q3 2019 Nov 14, 2019	BUY	$39.36 - $76.8 $63,290 - $123,494	1,608 Added 7.42%	23,273 $917,000
Q2 2019 Aug 14, 2019	BUY	$52.76 - $82.19 $1.04 Million - $1.63 Million	19,799 Added 1061.04%	21,665 $1.69 Million
Q1 2019 May 14, 2019	SELL	$27.39 - $68.41 $17,255 - $43,098	-630 Reduced 25.24%	1,866 $112,000
Q4 2018 Feb 14, 2019	SELL	$22.8 - $33.93 $186,960 - $278,226	-8,200 Reduced 76.66%	2,496 $72,000
Q3 2018 Nov 14, 2018	SELL	$29.75 - $43.08 $233,091 - $337,531	-7,835 Reduced 42.28%	10,696 $389,000
Q2 2018 Aug 14, 2018	BUY	$21.96 - $39.94 $396,334 - $720,837	18,048 Added 3736.65%	18,531 $700,000
Q1 2018 May 15, 2018	SELL	$17.1 - $26.61 $29,360 - $45,689	-1,717 Reduced 78.05%	483 $11,000
Q4 2017 Feb 14, 2018	SELL	$9.47 - $19.59 $28,694 - $59,357	-3,030 Reduced 57.93%	2,200 $43,000
Q3 2017 Nov 14, 2017	SELL	$7.7 - $9.6 $3,418 - $4,262	-444 Reduced 7.83%	5,230 $50,000
Q2 2017 Aug 14, 2017	BUY	N/A	274 Added 5.07%	5,674 $35,000
Q1 2017 Nov 14, 2017	BUY	N/A	5,400	5,400 $31,000

Others Institutions Holding QURE

# of Institutions

153

Shares Held

41M

Call Options Held

925K

Put Options Held

617K

View Full List

About uniQure N.V.

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $266M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

More about QURE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account